The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the most fatal and fastest growing cancers. Recently, nonalcoholic steatohepatitis (NASH) has been recognized as a major HCC catalyst. However, it is difficult to decipher the molecular mechanisms underlying the pathogenesis of NASH and understand how it progresses to HCC by studying humans. Progress in this field depends on the availability of reliable preclinical models amenable to genetic and functional analyses and exhibit robust NASH to HCC progression. Although numerous mouse models of NASH have been described, many do not faithfully mimic the human disease and few reliably progress to HCC. Here, we review current literature on the molecular etiology of NASH-related HCC and critically evaluate existing mouse models and their suitability for studying this malignancy. We also compare human transcriptomic and histopathological profiles with data from MUP-uPA mice, a reliable model of NASH-driven HCC that has been useful for evaluation of HCC-targeting immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“, 2017), despite the low mutational load associated with this type of cancer (Alexandrov et al., 2013).”
BackgroundAdipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1937 · Cited by 3,188
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 3×
“Up to 50% of newly diagnosed cases of HCC are in ‘virus-absent’ patients (ElSerag, 2011), most of whom present with obesity, non-alcoholic fatty liver disease (NAFLD), and, more commonly, non-alcoholic steatohepatitis (NASH), the most severe manifestation of NAFLD (Cohen et al., 2011).”
BackgroundmiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Self-citationSchulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 14×
“Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.”
BackgroundInfluentialSelf-citationHigh-Fat Diet Determines the Composition of the Murine Gut Microbiome Independently of Obesity
Hildebrandt, M. A., Hoffmann, C., Sherrill–Mix, S. A., Keilbaugh, S. A., Hamady, M., Chen, Y., Knight, R., Ahima, R. S., Bushman, F., & Wu, G. D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.042 · Cited by 1,576 · cited 1×
“In particular, HFD and obesity induce dysbiosis and increase the representation of inflammation-evoking bacteria in the gut (Hildebrandt et al., 2009; Parks et al., 2013; Shalapour et al., 2017).”
BackgroundThe impact of diet and lifestyle on gut microbiota and human health
Conlon, M., & Bird, A. (2014) · Nutrients · doi:10.3390/nu7010017 · Cited by 1,567
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 944
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver
Hsu, S.-H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H., Yu, L., Bai, S., La Perle, K., Chivukula, R. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63539 · Cited by 774
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., et al. (2016) · Nature · doi:10.1038/nature16969 · Cited by 766 · cited 1×
“A different NAFLD-related mechanism was described by Greten and coworkers (Ma et al., 2016), who attributed the decline in liver-resident CD4+ T cells in high-fat diet (HFD)-fed mice that express a MYC transgene (which is not a relevant model of NASH-driven HCC) to the production of linoleic acid by steatotic hepatocy…”
BackgroundThe Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757 · cited 1×
“collagen deposition in the liver, hepatic stellate cells (HSC), are related to activated myofibroblasts or cancer-associated fibroblasts (CAF), which are known to have broadspectrum tumor-promoting activities, not all of which are related to collagen deposition (Affo et al., 2017).”
BackgroundLiver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Marengo, A., Rosso, C., & Bugianesi, E. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-013832 · Cited by 755
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709
Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678
Self-citationEpidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
El-Serag, H. B., & Kanwal, F. (2014) · Hepatology · doi:10.1002/hep.27222 · Cited by 646
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634 · cited 2×
“Some of these metabolites, such as the bile acid deoxycholic acid, may also contribute to NASHto-HCC progression via yet-to-be identified mechanisms (Yoshimoto et al., 2013; Yu and Schwabe, 2017).”
BackgroundInflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
Self-citationTsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583
The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease
McCullough, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.004 · Cited by 580
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554
Parks, B. W., Nam, E., Org, E., Kostem, E., Norheim, F., Hui, S. T., Pan, C., Civelek, M., Rau, C. D., Bennett, B. J., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.007 · Cited by 544
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538
ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development
Nakagawa, H., Umemura, A., Taniguchi, K., Font-Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Valasek, M. A., Seki, E., Hidalgo, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.001 · Cited by 525
Self-citationThe Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498
Umemura, A., He, F., Taniguchi, K., Nakagawa, H., Yamachika, S., Font-Burgada, J., Zhong, Z., Subramaniam, S., Raghunandan, S., Duran, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.006 · Cited by 463
Self-citationNonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogenic Cirrhosis
Clark, J. M., & Diehl, A. M. (2003) · JAMA · doi:10.1001/jama.289.22.3000 · Cited by 428
Day, C. P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.017 · Cited by 395
Machado, M. V., Michelotti, G. A., Xie, G., de Almeida, T. P., Boursier, J., Bohnic, B., Guy, C. D., & Diehl, A. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127991 · Cited by 380
Obesity and Cancer: The Oil that Feeds the Flame
Font-Burgada, J., Sun, B., & Karin, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.015 · Cited by 356
Self-citationFujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355
Li, C., Deng, Y.-Q., Wang, S., Ma, F., Aliyari, R., Huang, X.-Y., Zhang, N.-N., Watanabe, M., Dong, H.-L., Liu, P., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.012 · Cited by 344
Yatsuji, S., Hashimoto, E., Tobari, M., Taniai, M., Tokushige, K., & Shiratori, K. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05640.x · Cited by 318
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
PNPLA3 I148M polymorphism and progressive liver disease
Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252 · cited 1×
“Such an imbalance is often the outcome of a sedentary lifestyle combined with overeating and excessive consumption of fructose-containing processed foods and beverages, but genetic factors (Dongiovanni et al., 2013) and inflammation of unknown origins (Marengo et al.”
BackgroundTeufel, A., Itzel, T., Erhart, W., Brosch, M., Wang, X. Y., Kim, Y. O., von Schönfels, W., Herrmann, A., Brückner, S., Stickel, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.051 · Cited by 229
Schierwagen, R., Maybüchen, L., Zimmer, S., Hittatiya, K., Bäck, C., Klein, S., Uschner, F. E., Reul, W., Boor, P., Nickenig, G., et al. (2015) · Scientific Reports · doi:10.1038/srep12931 · Cited by 179
Intestinal Microbiota and Nonalcoholic Steatohepatitis
Brandl, K., & Schnabl, B. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000349 · Cited by 169 · cited 2×
“As the gut microbiota is metabolically active, metabolomic studies have identified metabolomic profiles unique to NASH patients (Brandl and Schnabl, 2017).”
BackgroundHepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors
Dongiovanni, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12945 · Cited by 145
Dowman, J. K., Hopkins, L., Reynolds, G. M., Nikolaou, N., Armstrong, M. J., Shaw, J. C., Houlihan, D. D., Lalor, P. F., Tomlinson, J., Hübscher, S. G., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.01.034 · Cited by 131
Saito, K., Uebanso, T., Maekawa, K., Ishikawa, M., Taguchi, R., Nammo, T., Nishimaki‐Mogami, T., Udagawa, H., Fujii, M., Shibazaki, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep12466 · Cited by 86
Alkreathy, H. M., Khan, R. A., Khan, M. R., & Sahreen, S. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-452 · Cited by 84
Verbeek, J., Lannoo, M., Pirinen, E., Ryu, D., Spincemaille, P., Elst, I. V., Windmolders, P., Thevissen, K., Cammue, B. P. A., van Pelt, J. F., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-306748 · Cited by 79
The liver-specific microRNA miR-122: biology and therapeutic potential.
Filipowicz, W., & Grosshans, H. (2011) · Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques · doi:10.1007/978-3-7643-8989-5_11 · Cited by 70
Kishida, N., Matsuda, S., Itano, O., Shinoda, M., Kitago, M., Yagi, H., Abe, Y., Hibi, T., Masugi, Y., Aiura, K., et al. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0477-5 · Cited by 62
Current and future treatment options in non-alcoholic steatohepatitis (NASH)
Lazaridis, N., & Tsochatzis, E. A. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1293523 · Cited by 51
Mouse models of non‐alcoholic steatohepatitis: A reflection on recent literature
Haczeyni, F., Yeh, M. M., Ioannou, G. N., Leclercq, I. A., Goldin, R. D., Dan, Y. Y., Yu, J. Q., Teoh, N., & Farrell, G. C. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14122 · Cited by 48
Liver cholesterol: is it playing possum in NASH?
Farrell, G. C., & Rooyen, D. M. V. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00008.2012 · Cited by 41
Maurel, M., Samali, A., & Chevet, É. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.08.007 · Cited by 39
Takakura, K., Oikawa, T., Tomita, Y., Mizuno, Y., Nakano, M., Saeki, C., Torisu, Y., & Saruta, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i18.1989 · Cited by 23
Kammoun, H. L., Allen, T. L., Henstridge, D. C., Kraakman, M. J., Peijs, L., Rose‐John, S., & Febbraio, M. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179099 · Cited by 13
Self-citation
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.019 · Cited by 643
Targeting innate immune mediators in type 1 and type 2 diabetes
Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Metadata
- Authors
- Febbraio, M. A., Reibe, S., Shalapour, S., Ooi, G. J., Watt, M. J., & Karin, M.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 29
- Issue
- 1
- Pages
- 18-26
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2901814223
- Cited by
- 253
- References
- 64
- FWCI
- 14.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.